Drugs for Herpes Labialis (Oral Herpes) Market Report

Drugs for Herpes Labialis (Oral Herpes) Market - Global Professional Analysis and Forecast to 2026

  • POSTDATE：Dec 20, 2019
  • PAGES：213
  • REPORT CODE：GMM405335
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The worldwide Drugs for Herpes Labialis (Oral Herpes) market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.5% during the forecast period.

    This report presents the market size and development trends by detailing the Drugs for Herpes Labialis (Oral Herpes) market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Drugs for Herpes Labialis (Oral Herpes) market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Drugs for Herpes Labialis (Oral Herpes) industry and will help you to build a panoramic view of the industrial development.

    Drugs for Herpes Labialis (Oral Herpes) Market, By Type:

    • Aciclovir

    • Valacyclovir

    • Famciclovir

    • Docosanol

    • Other

    Drugs for Herpes Labialis (Oral Herpes) Market, By Application:

    • External Use

    • Oral

    • Injection

    Some of the leading players are as follows:

    • Haiwang

    • Cadila

    • Livzon

    • Mylan

    • Daewoong Pharmaceutical

    • Kelun Group

    • Teva

    • GSK

    • Luoxin

    • Carmex

    • Med shine

    • Bayer (Campho Phenique)

    • Blistex

    • Cipher

    • Apotex

    • Hikma

    • Novartis

    Geographically, Major regions are analyzed in details are as follows:

    • North America

    • Europe

    • Asia Pacific

    • Latin America

    • Middle East & Africa

  • Table of Contents

    1 Methodology and Scope

    • 1.1 Market Segmentation & Scope

      • 1.1.1 Technology Type

      • 1.1.2 Product

      • 1.1.3 Application

      • 1.1.4 Regional scope

      • 1.1.5 Estimates and forecast timeline

    • 1.2 Research Methodology

    • 1.3 Information Procurement

      • 1.3.1 Purchased database

      • 1.3.2 Internal database

      • 1.3.3 Secondary sources

      • 1.3.4 Primary research

      • 1.3.5 Details of primary research

    • 1.4 Information or Data Analysis

      • 1.4.1 Data analysis models

    • 1.5 Market Formulation & Validation

    • 1.6 Model Details

      • 1.6.1 Commodity flow analysis

      • 1.6.2 Volume price analysis

    • 1.7 List of Secondary Sources

    • 1.8 List of Abbreviations

    2 Executive Summary

    • 2.1 Market Outlook

    • 2.2 Segment Outlook

    3 Market Variables, Trends, & Scope

    • 3.1 Market Lineage Outlook

    • 3.1.1 Parent market outlook

      • 3.1.2 Ancillary market outlook

    • 3.2 Market Segmentation

      • 3.2.1 Analysis

    • 3.3 Market Dynamics

      • 3.3.1 Market driver analysis

      • 3.3.2 Market restraint analysis

      • 3.3.3 Industry opportunities

    • 3.4 Penetration & Growth Prospect Mapping

      • 3.4.1 Penetration & growth prospect mapping analysis

    • 3.5 Business Environment Analysis Tools

      • 3.5.1 Porter's five forces analysis

      • 3.5.2 PESTLE analysis

      • 3.5.3 Major deals & strategic alliances analysis

    4 Drugs for Herpes Labialis (Oral Herpes) Market: Technology Type Analysis

    • 4.1 Drugs for Herpes Labialis (Oral Herpes) Technology Type Market Share Analysis, 2018 & 2026

    • 4.2 Drugs for Herpes Labialis (Oral Herpes) Technology Type Market: Segment Dashboard

    • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

      • 4.3.1 Aciclovir

      • 4.3.2 Valacyclovir

      • 4.3.3 Famciclovir

      • 4.3.4 Docosanol

      • 4.3.5 Other

    5 Drugs for Herpes Labialis (Oral Herpes) Market: Product Analysis

    • 5.1 Drugs for Herpes Labialis (Oral Herpes) Product Market Share Analysis, 2018 & 2026

    • 5.2 Drugs for Herpes Labialis (Oral Herpes) Product Market: Segment Dashboard

    • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

    6 Drugs for Herpes Labialis (Oral Herpes) Market: Application Analysis

    • 6.1 Drugs for Herpes Labialis (Oral Herpes) Application Market Share Analysis, 2018 & 2026

    • 6.2 Drugs for Herpes Labialis (Oral Herpes) Application Market: Segment Dashboard

    • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

      • 6.3.1 External Use

      • 6.3.2 Oral

      • 6.3.3 Injection

    7 Drugs for Herpes Labialis (Oral Herpes) Market: Regional Analysis

    • 7.1 Drugs for Herpes Labialis (Oral Herpes) Regional Market Share Analysis, 2018 & 2026

    • 7.2 Drugs for Herpes Labialis (Oral Herpes) Regional Market: Segment Dashboard

    • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

    • 7.4 List of Players at Regional Level

      • 7.4.1 North America

      • 7.4.2 Europe

      • 7.4.3 Asia Pacific

    • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

      • 7.5.1 North America

      • 7.5.2 Europe

      • 7.5.3 Asia Pacific

      • 7.5.4 Latin America

      • 7.5.5 MEA

    • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

      • 7.6.1 North America

      • 7.6.2 Europe

      • 7.6.3 Asia Pacific

      • 7.6.4 Latin America

      • 7.6.5 Middle East & Africa

    8 Competitive Analysis

    • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

    • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

    • 8.3 Vendor Landscape

      • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

    9 Company Profiles

    • 9.1 Haiwang

      • 9.1.1 Haiwang Company overview

      • 9.1.2 Financial performance

      • 9.1.3 Product benchmarking

      • 9.1.4 Strategic initiatives

      • 9.1.5 SWOT analysis

    • 9.2 Cadila

      • 9.2.1 Cadila Company overview

      • 9.2.2 Financial performance

      • 9.2.3 Product benchmarking

      • 9.2.4 Strategic initiatives

      • 9.2.5 SWOT analysis

    • 9.3 Livzon

      • 9.3.1 Livzon Company overview

      • 9.3.2 Financial performance

      • 9.3.3 Product benchmarking

      • 9.3.4 Strategic initiatives

      • 9.3.5 SWOT analysis

    • 9.4 Mylan

      • 9.4.1 Mylan Company overview

      • 9.4.2 Financial performance

      • 9.4.3 Product benchmarking

      • 9.4.4 Strategic initiatives

      • 9.4.5 SWOT analysis

    • 9.5 Daewoong Pharmaceutical

      • 9.5.1 Daewoong Pharmaceutical Company overview

      • 9.5.2 Financial performance

      • 9.5.3 Product benchmarking

      • 9.5.4 Strategic initiatives

      • 9.5.5 SWOT analysis

    • 9.6 Kelun Group

      • 9.6.1 Kelun Group Company overview

      • 9.6.2 Financial performance

      • 9.6.3 Product benchmarking

      • 9.6.4 Strategic initiatives

      • 9.6.5 SWOT analysis

    • 9.7 Teva

      • 9.7.1 Teva Company overview

      • 9.7.2 Financial performance

      • 9.7.3 Product benchmarking

      • 9.7.4 Strategic initiatives

      • 9.7.5 SWOT analysis

    • 9.8 GSK

      • 9.8.1 GSK Company overview

      • 9.8.2 Financial performance

      • 9.8.3 Product benchmarking

      • 9.8.4 Strategic initiatives

      • 9.8.5 SWOT analysis

    • 9.9 Luoxin

      • 9.9.1 Luoxin Company overview

      • 9.9.2 Financial performance

      • 9.9.3 Product benchmarking

      • 9.9.4 Strategic initiatives

      • 9.9.5 SWOT analysis

    • 9.10 Carmex

      • 9.10.1 Carmex Company overview

      • 9.10.2 Financial performance

      • 9.10.3 Product benchmarking

      • 9.10.4 Strategic initiatives

      • 9.10.5 SWOT analysis

    • 9.11 Med shine

      • 9.11.1 Med shine Company overview

      • 9.11.2 Financial performance

      • 9.11.3 Product benchmarking

      • 9.11.4 Strategic initiatives

      • 9.11.5 SWOT analysis

    • 9.12 Bayer (Campho Phenique)

      • 9.12.1 Bayer (Campho Phenique) Company overview

      • 9.12.2 Financial performance

      • 9.12.3 Product benchmarking

      • 9.12.4 Strategic initiatives

      • 9.12.5 SWOT analysis

    • 9.13 Blistex

      • 9.13.1 Blistex Company overview

      • 9.13.2 Financial performance

      • 9.13.3 Product benchmarking

      • 9.13.4 Strategic initiatives

      • 9.13.5 SWOT analysis

    • 9.14 Cipher

      • 9.14.1 Cipher Company overview

      • 9.14.2 Financial performance

      • 9.14.3 Product benchmarking

      • 9.14.4 Strategic initiatives

      • 9.14.5 SWOT analysis

    • 9.15 Apotex

      • 9.15.1 Apotex Company overview

      • 9.15.2 Financial performance

      • 9.15.3 Product benchmarking

      • 9.15.4 Strategic initiatives

      • 9.15.5 SWOT analysis

    • 9.16 Hikma

      • 9.16.1 Hikma Company overview

      • 9.16.2 Financial performance

      • 9.16.3 Product benchmarking

      • 9.16.4 Strategic initiatives

      • 9.16.5 SWOT analysis

    • 9.17 Novartis

      • 9.17.1 Novartis Company overview

      • 9.17.2 Financial performance

      • 9.17.3 Product benchmarking

      • 9.17.4 Strategic initiatives

      • 9.17.5 SWOT analysis

     

    The List of Tables and Figures (Totals 94 Figures and 131 Tables)

    • Figure Aciclovir Drugs for Herpes Labialis (Oral Herpes) market, 2015 - 2026 (USD Million)

    • Figure Valacyclovir Drugs for Herpes Labialis (Oral Herpes) market, 2015 - 2026 (USD Million)

    • Figure Famciclovir Drugs for Herpes Labialis (Oral Herpes) market, 2015 - 2026 (USD Million)

    • Figure Docosanol Drugs for Herpes Labialis (Oral Herpes) market, 2015 - 2026 (USD Million)

    • Figure Other Drugs for Herpes Labialis (Oral Herpes) market, 2015 - 2026 (USD Million)

    • Figure External Use market, 2015 - 2026 (USD Million)

    • Figure Oral market, 2015 - 2026 (USD Million)

    • Figure Injection market, 2015 - 2026 (USD Million)

    • Table List of players in North America

    • Table List of players in Europe

    • Table List of players in Asia Pacific

    • Table SWOT analysis

    • Table North America Drugs for Herpes Labialis (Oral Herpes) market, by country, 2015 - 2026 (USD Million)

    • Table North America Drugs for Herpes Labialis (Oral Herpes) market, by type, 2015 - 2026 (USD Million)

    • Table North America Drugs for Herpes Labialis (Oral Herpes) market, by product, 2015 - 2026 (USD Million)

    • Table North America Drugs for Herpes Labialis (Oral Herpes) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table U.S. Drugs for Herpes Labialis (Oral Herpes) market, by type, 2015 - 2026 (USD Million)

    • Table U.S. Drugs for Herpes Labialis (Oral Herpes) market, by product, 2015 - 2026 (USD Million)

    • Table U.S. Drugs for Herpes Labialis (Oral Herpes) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Canada Drugs for Herpes Labialis (Oral Herpes) market, by type, 2015 - 2026 (USD Million)

    • Table Canada Drugs for Herpes Labialis (Oral Herpes) market, by product, 2015 - 2026 (USD Million)

    • Table Canada Drugs for Herpes Labialis (Oral Herpes) market, by application, 2015 - 2026 (USD Million)

    • Table Europe Drugs for Herpes Labialis (Oral Herpes) market, by country, 2015 - 2026 (USD Million)

    • Table Europe Drugs for Herpes Labialis (Oral Herpes) market, by type, 2015 - 2026 (USD Million)

    • Table Europe Drugs for Herpes Labialis (Oral Herpes) market, by product, 2015 - 2026 (USD Million)

    • Table Europe Drugs for Herpes Labialis (Oral Herpes) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table U.K. Drugs for Herpes Labialis (Oral Herpes) market, by type, 2015 - 2026 (USD Million)

    • Table U.K. Drugs for Herpes Labialis (Oral Herpes) market, by product, 2015 - 2026 (USD Million)

    • Table U.K. Drugs for Herpes Labialis (Oral Herpes) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Germany Drugs for Herpes Labialis (Oral Herpes) market, by type, 2015 - 2026 (USD Million)

    • Table Germany Drugs for Herpes Labialis (Oral Herpes) market, by product, 2015 - 2026 (USD Million)

    • Table Germany Drugs for Herpes Labialis (Oral Herpes) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table France Drugs for Herpes Labialis (Oral Herpes) market, by type, 2015 - 2026 (USD Million)

    • Table France Drugs for Herpes Labialis (Oral Herpes) market, by product, 2015 - 2026 (USD Million)

    • Table France Drugs for Herpes Labialis (Oral Herpes) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Italy Drugs for Herpes Labialis (Oral Herpes) market, by type, 2015 - 2026 (USD Million)

    • Table Italy Drugs for Herpes Labialis (Oral Herpes) market, by product, 2015 - 2026 (USD Million)

    • Table Italy Drugs for Herpes Labialis (Oral Herpes) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Spain Drugs for Herpes Labialis (Oral Herpes) market, by type, 2015 - 2026 (USD Million)

    • Table Spain Drugs for Herpes Labialis (Oral Herpes) market, by product, 2015 - 2026 (USD Million)

    • Table Spain Drugs for Herpes Labialis (Oral Herpes) market, by application, 2015 - 2026 (USD Million)

    • Table Asia Pacific Drugs for Herpes Labialis (Oral Herpes) market, by country, 2015 - 2026 (USD Million)

    • Table Asia Pacific Drugs for Herpes Labialis (Oral Herpes) market, by type, 2015 - 2026 (USD Million)

    • Table Asia Pacific Drugs for Herpes Labialis (Oral Herpes) market, by product, 2015 - 2026 (USD Million)

    • Table Asia Pacific Drugs for Herpes Labialis (Oral Herpes) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table China Drugs for Herpes Labialis (Oral Herpes) market, by type, 2015 - 2026 (USD Million)

    • Table China Drugs for Herpes Labialis (Oral Herpes) market, by product, 2015 - 2026 (USD Million)

    • Table China Drugs for Herpes Labialis (Oral Herpes) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Japan Drugs for Herpes Labialis (Oral Herpes) market, by type, 2015 - 2026 (USD Million)

    • Table Japan Drugs for Herpes Labialis (Oral Herpes) market, by product, 2015 - 2026 (USD Million)

    • Table Japan Drugs for Herpes Labialis (Oral Herpes) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table India Drugs for Herpes Labialis (Oral Herpes) market, by type, 2015 - 2026 (USD Million)

    • Table India Drugs for Herpes Labialis (Oral Herpes) market, by product, 2015 - 2026 (USD Million)

    • Table India Drugs for Herpes Labialis (Oral Herpes) market, by application, 2015 - 2026 (USD Million)

    • Table Latin America Drugs for Herpes Labialis (Oral Herpes) market, by country, 2015 - 2026 (USD Million)

    • Table Latin America Drugs for Herpes Labialis (Oral Herpes) market, by type, 2015 - 2026 (USD Million)

    • Table Latin America Drugs for Herpes Labialis (Oral Herpes) market, by product, 2015 - 2026 (USD Million)

    • Table Latin America Drugs for Herpes Labialis (Oral Herpes) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Brazil Drugs for Herpes Labialis (Oral Herpes) market, by type, 2015 - 2026 (USD Million)

    • Table Brazil Drugs for Herpes Labialis (Oral Herpes) market, by product, 2015 - 2026 (USD Million)

    • Table Brazil Drugs for Herpes Labialis (Oral Herpes) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Mexico Drugs for Herpes Labialis (Oral Herpes) market, by type, 2015 - 2026 (USD Million)

    • Table Mexico Drugs for Herpes Labialis (Oral Herpes) market, by product, 2015 - 2026 (USD Million)

    • Table Mexico Drugs for Herpes Labialis (Oral Herpes) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Argentina Drugs for Herpes Labialis (Oral Herpes) market, by type, 2015 - 2026 (USD Million)

    • Table Argentina Drugs for Herpes Labialis (Oral Herpes) market, by product, 2015 - 2026 (USD Million)

    • Table Argentina Drugs for Herpes Labialis (Oral Herpes) market, by application, 2015 - 2026 (USD Million)

    • Table MEA Drugs for Herpes Labialis (Oral Herpes) market, by country, 2015 - 2026 (USD Million)

    • Table MEA Drugs for Herpes Labialis (Oral Herpes) market, by type, 2015 - 2026 (USD Million)

    • Table MEA Drugs for Herpes Labialis (Oral Herpes) market, by product, 2015 - 2026 (USD Million)

    • Table MEA Drugs for Herpes Labialis (Oral Herpes) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table South Africa Drugs for Herpes Labialis (Oral Herpes) market, by type, 2015 - 2026 (USD Million)

    • Table South Africa Drugs for Herpes Labialis (Oral Herpes) market, by product, 2015 - 2026 (USD Million)

    • Table South Africa Drugs for Herpes Labialis (Oral Herpes) market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Nigeria Drugs for Herpes Labialis (Oral Herpes) market, by type, 2015 - 2026 (USD Million)

    • Table Nigeria Drugs for Herpes Labialis (Oral Herpes) market, by product, 2015 - 2026 (USD Million)

    • Table Nigeria Drugs for Herpes Labialis (Oral Herpes) market, by application, 2015 - 2026 (USD Million)

    • Table Recent Developments & Impact Analysis, by Key Market Participants

    • Table Recent Developments & Impact Analysis, by Key Market Participants

    • Table Company market position analysis

    • Table Company Profiles

    • Table Haiwang Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Cadila Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Livzon Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Mylan Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Daewoong Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Kelun Group Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Teva Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table GSK Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Luoxin Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Carmex Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Med shine Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Bayer (Campho Phenique) Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Blistex Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Cipher Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Apotex Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Hikma Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Novartis Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US